checkAd

Bioceres Crop Solutions Reports Fiscal Third Quarter 2021 Operational and Financial Results

Nachrichtenquelle: Business Wire (engl.)
13.05.2021, 12:00  |  145   |   |   

Bioceres Crop Solutions Corp. (“Bioceres”) (NASDAQ: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported its financial results for the fiscal third quarter ended March 31, 2021. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (“YoY”), unless noted otherwise.

Fiscal Third Quarter & Subsequent Financial & Operational Highlights

  • HB4 wheat on track with over 60,000 hectares already contracted for upcoming planting season, representing over 200 different growers and +550 locations. Approximately half of total hectares onboarded via beta version of digital platform.
  • HB4 soy harvest 60% completed. In late 2020, drought-tolerant HB4 soy was planted on approximately 23,000 hectares.
  • Agreement with upscale consumer brand Havanna to develop and roll out HB4 wheat-derived products with improved environmental footprint and farm-to-fork traceability.
  • Contribution of non-core GLA rights into Moolec Science in exchange for 6% ownership. Investment allows the Company to enter fast growing alternative food market and complements efforts to enable the transition of food systems towards carbon neutrality.
  • Comparable revenues up 35% to $35.0 million in third quarter of fiscal 2021. Crop nutrition expansion was the main growth catalyst for the quarter driven by a 466% growth of micro-beaded fertilizers sales. For the trailing twelve months total comparable revenues increased 12% to $177.0 million compared to the year-ago period, and Adjusted EBITDA increased 14% to $46.4 million.
  • Bioceres subsidiary Rizobacter Argentina S.A. completed a $26.0 million public offering of Series V corporate bonds in the Argentine capital market.
  • Completed transfer of stock exchange listing from the NYSE American to The Nasdaq Global Select Market. New listing enhances visibility as an Ag-Tech company focused on sustainable solutions.

ESG Initiatives:

  • We have commissioned Vigeo Eiris1 to produce an independent opinion on the alignment of our sustainability-linked financing framework with IMCA’s SLBP 2020. The global leader in ESG assessment is of the opinion that Bioceres’ selected KPI: “Tons of CO2 equivalent cumulative savings in soy/wheat primary production systems”, results relevant, coherent and material from an environmental standpoint, as well as it reflects relevant sustainability challenges for the activities of the Company related to the Agriculture sector, mainly United Nations’ Sustainable Development Goals (“SDGs” 2 & 13), namely Zero Hunger and Climate Action. Moreover, the Framework sets Bioceres to achieve ambitious goal of 156,000+ tons of CO2 eq. cumulative savings by 2025 as HB4 soy and wheat roll out projections are met.

1 V.E. is a global leader in ESG assessments, data, research, benchmarks and analytics. Leveraging on extensive proprietary database, they equip market players with the ESG insight needed to manage risks and better understand and address social and environmental impact. Since 2019, V.E has been an Affiliate of Moody’s Corporation. For further information please visit: vigeo-eiris.com

MANAGEMENT COMMENTARY

Mr. Federico Trucco, Bioceres Chairman & Chief Executive Officer, commented: “The positive performance of HB4 wheat varieties observed during the last crop cycle, as reported in our second quarter’s earnings call, has created excellent pre-season momentum, with contracts already in place for over 60,000 hectares, our baseline target prior to Brazil import approval. We are also progressing with HB4 soy harvest, which is currently at 60%. Resulting seed inventories for both crops should put us in a good place for a meaningful launch once China and Brazil approve HB4 in soy and wheat, respectively.”

“As we progress in developing and scaling locally adapted HB4 seeds, as well as on the regulatory front, we are also moving forward with two additional aspects aimed at maximizing this opportunity. We have onboarded close to half of HB4 Program growers via our Generation HB4 digital platform, fully automating the commercial interaction, credit scoring, contract execution and input logistics. On the downstream front, we have validated HB4’s sustainability framework and entered a first agreement with a consumer brand, Havanna, for HB4 wheat-derived products. The direct interaction with consumers leveraging on the farm-to-fork traceability of the HB4 Program and associated environmental metrics, represents a tangible example of how technology may be used towards re-building agriculture’s social license while keeping food affordable.”

Mr. Enrique Lopez Lecube, Chief Financial Officer of Bioceres, said: “On the financial front, the third quarter of 2021 experienced top-line revenue growth of 35% as our crop nutrition segment was the main growth catalyst driven by micro-beaded fertilizers sales. The combination of this and operating leverage enabled the Company to deliver improved adjusted EBITDA and margin expansion during the third quarter of fiscal 2021, positioning our financial profile into the LTM double digit growth trajectory.”

“In summary, I believe Bioceres is firing on all cylinders as we now have financial flexibility to execute our HB4 Program, our cost of capital has been reduced, and our financial performance is building while exploiting leverage in our model. We look forward to sharing more on our developing story at upcoming investor conferences in the coming months,” concluded Lopez Lecube.

Key Operational Metrics (Figures in millions of US dollars, unless otherwise noted)

HB4 Wheat and HB4 Soy Metrics

Operational metrics to be updated in the upcoming quarter, 4Q21, at end of HB4 soy harvest and HB4 wheat planting.

Table 1: Key Financial Metrics (Figures in millions of US dollars, unless otherwise noted)

3Q21

As Reported

% Change

 

Revenue by Segment

3Q20

3Q21

Reported

Comparable¹

Crop Protection

16.6

17.3

4%

(3%)

Seed and Integrated Products

4.0

3.7

(9%)

(9%)

Crop Nutrition

5.0

15.2

203%

191%

Total Revenue

25.7

36.2

41%

35%

Gross Profit

10.8

15.3

42%

45%

Gross Margin

41.9%

42.3%

41 bps

362 bps

Adjusted EBITDA

2.6

6.9

163%

 

Adjusted EBITDA Margin

10.2%

19.0%

881 bps

 

1.

Comparable excludes the impact of IAS29 as discussed in more detail on page 17.

Table 2: Key Financial Metrics (Figures in millions of US dollars, unless otherwise noted)

Fiscal Nine-Month Period

As Reported

% Change

 
Revenue by Segment

9M20

9M21

Reported

Comparable¹

Crop Protection

67.7

66.0

(3%)

(3%)

Seed and Integrated Products

23.5

24.8

6%

10%

Crop Nutrition

33.7

36.5

8%

7%

Total Revenue

124.9

127.3

2%

2%

Gross Profit

56.7

58.2

3%

5%

Gross Margin

45.4%

45.7%

35 bps

141 bps

Adjusted EBITDA

31.8

31.7

(0%)

 

Adjusted EBITDA Margin

25.5%

24.9%

(58 bps)

 

Cash & Cash Equivalents

54.3

49.2

(9%)

 

Net Debt to LTM EBITDA

2.30x

2.89x

 

 

LTM EBITDA

40.6

46.4

14%

 

1.

Comparable excludes the impact of IAS29 as discussed in more detail on page 17.

For a full version of Bioceres Fiscal Third Quarter 2021 Earnings Release, click here.

FISCAL THIRD QUARTER 2021 EARNINGS CONFERENCE CALL

Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Máximo Goya will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the company’s website here.

To access the call, please use the following information:

Date:

Thursday, May 13, 2021

Time:

8:30 a.m. EDT, 5:30 a.m. PDT

Toll Free dial-in number:

1-844-839-9680

Toll/International dial-in number:

1-647-689-2346

Conference ID:

2683788

Pre-Register conference call:

Click here

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.

The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.

A replay of the call will be available until May 18, 2021 following the conference.

Toll Free Replay Number:

1-800-585-8367

International Replay Number:

1-416-621-4642

Replay ID:

2683788

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated global provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. The Company's solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4 program, the Company is bringing digital solutions to support growers' decisions and provide end-to-end traceability for production outputs. For more information, click here.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

 

Unaudited Consolidated Statement of Comprehensive Income

(Figures in US dollars)

 

Three-month
period ended
03/31/2021

Three-month
period ended
03/31/2020

 

Nine-month
period ended
03/31/2021

Nine-month
period ended
03/31/2020

Total revenue

Cost of sales

36,221,113

(20,901,909)

25,672,412

(14,920,088)

 

127,315,064

(69,088,393)

124,918,358

(68,227,890)

Gross profit

% Gross profit

15,319,204

42%

10,752,324

42%

 

58,226,671

46%

56,690,468

45%

Operating expenses

Share of profit of JV

Other income or expenses, net

(11,656,378)

906,241

205,127

(9,953,025)

(132,080)

(22,098)

 

(35,107,369)

1,211,928

345,449

(31,262,696)

1,166,425

(203,664)

Operating profit

4,774,194

645,121

 

24,676,679

26,390,533

Finance result

(5,008,001)

(4,584,952)

 

(23,640,337)

(24,453,628)

Profit / (loss) before income tax

(233,807)

(3,939,831)

 

1,036,342

1,936,905

Income tax

(390,710)

366,382

 

(6,232,163)

(838,273)

Profit / (loss) for the period

(624,517)

(3,573,449)

 

(5,195,821)

1,098,632

Other comprehensive income / (loss)

1,911,937

(56,919)

 

2,707,064

(7,623,444)

Total comprehensive profit / (loss)

1,287,420

(3,630,368)

 

(2,488,757)

(6,524,812)

Profit / (loss) for the period attributable to:

 

 

 

 

 

Equity holders of the parent

Non-controlling interests

(1,180,484)

555,967

(3,120,733)

(452,716)

 

(7,503,849)

2,308,028

1,143,771

(45,139)

 

(624,517)

(3,573,449)

 

(5,195,821)

1,098,632

Total comprehensive profit / (loss) attributable to:

 

 

 

 

 

Equity holders of the parent

Non-controlling interests

510,325

777,095

(3,170,432)

(459,936)

 

(5,278,946)

2,790,189

(5,597,750)

(927,062)

 

1,287,420

(3,630,368)

 

(2,488,757)

(6,524,812)

 

Unaudited Consolidated Statement of Financial Position

 

 

(Figures in US dollars)

 

 

ASSETS

03/31/2021

06/30/2020

 

CURRENT ASSETS

 

 

Cash and cash equivalents

16,784,080

27,159,421

Other financial assets

32,415,344

28,799,833

Trade receivables

80,412,576

73,546,633

Other receivables

7,855,945

4,770,672

Income and minimum presumed income taxes recoverable

167,745

112,220

Inventories

39,058,808

29,338,548

Biological assets

17,101,794

965,728

Total current assets

193,796,292

164,693,055

 

 

NON-CURRENT ASSETS

 

 

Other financial assets

333,969

322,703

Trade receivables

831,581

-

Other receivables

2,169,173

1,703,573

Income and minimum presumed income taxes recoverable

10,288

6,029

Deferred tax assets

2,776,265

2,693,195

Investments in joint ventures and associates

29,287,990

24,652,792

Property, plant and equipment

42,845,194

41,515,106

Intangible assets

61,093,033

35,333,464

Goodwill

26,480,645

25,526,855

Right-of-use leased asset

1,080,939

1,114,597

Total non-current assets

166,909,077

132,868,314

Total assets

360,705,369

297,561,369

 

 

LIABILITIES

03/31/2021

06/30/2020

CURRENT LIABILITIES

 

 

Trade and other payables

60,402,061

57,289,862

Borrowings

85,415,020

63,721,735

Employee benefits and social security

3,622,544

4,510,592

Deferred revenue and advances from customers

1,388,479

2,865,437

Income tax payable

5,049,721

1,556,715

Government grants

1,302

1,270

Consideration for acquisition of assets

200,000

-

Lease liability

507,434

665,098

Total current liabilities

156,586,561

130,610,709

 

 

NON-CURRENT LIABILITIES

 

 

Trade and other payables

452,654

452,654

Borrowings

50,740,811

41,226,610

Employee benefits and social security

-

534,038

Government grants

-

2,335

Investments in joint ventures and associates

1,266,645

1,548,829

Deferred tax liabilities

17,630,027

16,858,125

Provisions

377,900

417,396

Consideration for acquisition of assets

7,637,972

-

Warrants

-

1,686,643

Convertible notes

47,197,434

43,029,834

Lease liability

428,304

444,714

Total non-current liabilities

125,731,747

106,201,178

Total liabilities

282,318,308

236,811,887

 

 

EQUITY

 

 

Equity attributable to owners of the parent

61,026,785

46,179,395

Non-controlling interests

17,360,276

14,570,087

Total equity

78,387,061

60,749,482

Total equity and liabilities

360,705,369

297,561,369

 

Kohlendioxid jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Bioceres Crop Solutions Reports Fiscal Third Quarter 2021 Operational and Financial Results Bioceres Crop Solutions Corp. (“Bioceres”) (NASDAQ: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported its financial results for the fiscal third …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel